Stock Sale, Buyback News

SAN FRANCISCO--(BUSINESS WIRE)--SoFi Technologies, Inc. (NASDAQ: SOFI) (“SoFi” or the “Company”) today announced that it has priced its previously announced underwritten public offering of 54,545,454 shares of its common stock at a price of $27.50 per share, for total gross proceeds of approximately $1.5 billion, before deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, SoFi has granted the underwriters a 30-day option to purchase up to a...

SAN FRANCISCO--(BUSINESS WIRE)--SoFi Technologies, Inc. (NASDAQ: SOFI) (“SoFi” or the “Company”) today announced an underwritten public offering of $1.5 billion of shares of its common stock. In connection with the offering, SoFi expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. All of the shares of common stock in the offering will be sold by SoFi. SoFi intends to use the net proceeds from the offering fo...

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--Unum Group (NYSE: UNM) announced today that its board of directors has approved a new share repurchase program authorizing the company to repurchase up to $1 billion of its common stock from time to time beginning on January 1, 2026. The company’s current share repurchase program will continue in effect through December 31, 2025, at which time the current program will terminate and all subsequent repurchases will take place under the new program. The timing...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 88,000 shares of common stock to four new employees under the Company’s 2024 Indu...

SALT LAKE CITY--(BUSINESS WIRE)--ReposiTrak (NYSE: TRAK), the world's largest food traceability and regulatory compliance network, built upon its proven inventory management and out-of-stock reduction SaaS platform, today announced that its Board of Directors has approved a new 10B5-1 share repurchase program, authorizing the repurchase of up to $2 million of the Company's common stock. This 10B5-1 is included in the previously approved share repurchase program of up to $21 million, of which $7...

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH) (NeuPath or the “Company”) announced today that the TSX Venture Exchange (the “Exchange”) has accepted a notice filed by NeuPath of its intention to renew its normal course issuer bid (“NCIB”). Under the NCIB, the Company may, during the 12-month period commencing December 4, 2025 and ending December 3, 2026 (or on such date that the Company completes its purchases or provides notice of termination), purchase up to 2,527,224 common share...

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS) (“UL Solutions”) today announced the pricing of its underwritten public offering (the “offering”) of 12,500,000 shares of its Class A common stock at a public offering price of $78.00 per share. The offering consists entirely of secondary shares to be sold by UL Standards & Engagement (the “selling stockholder”). The underwriters have a 30-day option to purchase up to an additional 1,875,000 shares of Class A common stock from...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...

NEW YORK--(BUSINESS WIRE)--The Board of Directors of General American Investors Company, Inc., a closed-end investment company whose common and preferred shares are listed on the New York Stock Exchange (NYSE symbols - GAM and GAM Pr B, respectively), renewed authorization for the repurchase of up to 1,601,553 outstanding shares of 5.95% Cumulative Preferred Stock, Series B when the shares are trading at a market price below the liquidation preference of $25 per share. To date, a total of 398,4...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto’s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto’s common stock. The stock option was granted under Alto’s 2025 Inducement Plan as a mate...